Older and new purine nucleoside analogs for patients with acute leukemias

Cancer Treatment Reviews

Volumn 39, Issue 8, 2013, Pages 851-861

  Robak, Pawel ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

2 CdA; ALL; AML; Cladribine; Clofarabine; Fludarabine; Forodesine; Nelarabine; Purine nucleoside analogs

Indexed keywords

AMSACRINE; CARBOPLATIN; CLADRIBINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; DNA POLYMERASE; DOXORUBICIN; FLUDARABINE; FORODESINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; NELARABINE; PENTOSTATIN; PURINE NUCLEOSIDE DERIVATIVE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PHASE; CELL PROLIFERATION; CONTINUOUS INFUSION; DNA REPAIR; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; LYMPHOBLASTOMA; LYMPHOMA; MITOSIS; NONHUMAN; PROGRESSION FREE SURVIVAL; PURINE METABOLISM; REVIEW; RNA SYNTHESIS; SALVAGE THERAPY; T LYMPHOCYTE;

2-CDA; ALL; AML; CLADRIBINE; CLOFARABINE; FLUDARABINE; FORODESINE; NELARABINE; PURINE NUCLEOSIDE ANALOGS;

ACUTE DISEASE; CELL GROWTH PROCESSES; HUMANS; LEUKEMIA; PURINE NUCLEOSIDES;

EID: 84883550969     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.03.006     Document Type: Review

References (136)

1. Deschler B., Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006, 107:2099-2107.
2. Aquino V.M. Acute myelogenous leukemia. Curr Probl Pediatr Adolesc Health Care 2002, 32:50-58.
3. Atlanta GACS. Cancer facts and figures. 2012.
4. Robak T., Szmigielska-Kapłon A., Pluta A., et al. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Curr Med Chem 2011, 18:638-666.
5. Robak T., Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009, 2:2349-2370.
6. Farhi D.C., Rosenthal N.S. Acute lymphoblastic leukemia. Clin Lab Med 2000, 20:17-28.
7. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166-178.
8. Hoelzer D., Gokbuget N. New approaches in acute lymphoblastic leukemia in adults: where do we go?. Semin Oncol 2000, 27:540-559.
9. Pui C.H., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. N Engl J Med 2004, 350:1535-1548.
10. Parker W.B. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev 2009, 109:2880-2893.
11. Pettit A.R. Mechanism of action of purine analogues in chronic lymphocytic leukemia. Br J Haematol 2003, 121:692-702.
12. Korycka A., Lech-Marańda E., Robak T. Novel purine nucleoside analogues for hematological malignancies. Recent Pat Anticancer Drug Discov 2008, 3:123-136.
13. Robak T., Lech-Maranda E., Korycka A., Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006, 13:3165-3189.
14. Parker W.B. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev 2009, 109:2880-2893.
15. Robak T. Purine nucleoside analogues in the treatment of myleoid leukemias. Leuk Lymphoma 2003, 44:391-409.
16. Robak T., Jamroziak K., Gora-Tybor J., et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010, 28:1863-1869.
17. Robak T. New nucleoside analogs for patients with hematological malignancies. Expert Opin Investig Drugs 2011, 20:343-359.
18. Rodriquez C.O., Mitchell B.S., Ayres M., Eriksson S., Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 2002, 62:3100-3105.
19. Adkins J.C., Peters D.H., Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997, 53:1005-1037.
20. Foran J.M., Oscier D., Orchard J., et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non- Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 1999, 17:1574-1579.
21. Van den Neste E., Cardoen S., Offner F., Bontemps F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). Int J Oncol 2005, 27:1113-1124.
22. Robak T., Korycka A., Lech-Maranda E., Robak P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 2009, 14:1183-1226.
23. Robak T., Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des 2012, 18:3373-3388.
24. Jackson G.H. Use of fludarabine in the treatment of acute myeloid leukemia. Hematol J 2004, 5(SUPPL. 1):S62-S67.
25. Estey E., Plunkett W., Gandhi V., et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993, 9:343-350.
26. Vidarsson B., Abonour R., Williams E.C., et al. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Leuk Lymphoma 2001, 41:321-331.
27. Ferrara F., Palmieri S., Izzo T., Criscuolo C., Riccardi C. Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloidleukaemia secondary to a previously diagnosed myelodysplastic syndrome. Hematol Oncol 2010, 28:202-208.
28. Mehta D.R., Foon K.A., Redner R.L., et al. Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy. Leuk Res 2011, 35:885-888.
29. Estey E.H., Thall P.F., Pierce S., et al. Randomized phase II study of fludarabine+cytosine arabinoside+idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999, 93:2478-2484.
30. Visani G., Tosi P., Zinzani P.L., et al. FLAG (fludarabine+high-dose cytarabine+G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia 1994, 8:1842-1846.
31. Ferrara F., Palmieri S., Pocali B., et al. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol 2002, 68:203-209.
32. Tedeschi A., Montillo M., Ferrara F., et al. Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG). Eur J Haematol 2000, 64:182-187.
33. Ossenkoppele G.J., Graveland W.J., Sonneveld P., et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 2004, 103:2908-2913.
34. Montillo M., Mirto S., Petti M.C., et al. Fludarabine cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998, 58:105-109.
35. de la Rubia J., Regadera A., Martín G., et al. FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leuk Res 2002, 26:725-730.
36. Steinmetz H.T., Schulz A., Staib P., et al. Phase II trial or idarubicin, fludarabine, cytosine arabinoside and filigastim (Ida-FLAG) for treatment of refractory, relapsed and secondary AML. Ann Hematol 1999, 78:418-425.
37. Russo D., Pricolo G., Michieli M., et al. Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia. Leuk Lymphoma 2001, 40:335-343.
38. Kim I., Koh Y., Yoon S.S., Park S., et al. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. Am J Hematol 2013, 88:10-15.
39. Tavil B., Aytac S., Balci Y.I., et al. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience. Pediatr Hematol Oncol 2010, 27:517-528.
40. Martin M.G., Augustin K.M., Uy G.L., et al. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. Am J Hematol 2009, 84:733-737.
41. Melillo L., Valente D., D'Arena G., et al. Combination treatment of flag with non-pegylated liposomal doxorubicin (MYOCET(TM)) in elderly patients with acute myeloid leukemia: a single center experience. Int J Immunopathol Pharmacol 2011, 24:703-709.
42. Clavio M., Venturino C., Pierri I., et al. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol 2004, 83:696-703.
43. Jackson G.H. Use of fludarabine in the treatment of acute myeloid leukemia. Hematol J 2004, 5(SUPPL. 1):S62-S67.
44. Warell R.P., Berman E. Phase I and II study of fludarabine phosphate in leukemia therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986, 4:740-779.
45. Spriggs D.R., Stopa E., Mayer R.J., Schoene W., Kufe D.W. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res 1986, 46:5953-5958.
46. Chun H.G., Leyland-Jones B.R., Caryk S.M., Hoth D.F. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986, 70:1225-1228.
47. Keating M.J., O'Brien S., Robertson L.E., et al. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma 1994, 14(Suppl 2):11-16.
48. Cooper B.W., Veal G.J., Radivoyevitch T., et al. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. Clin Cancer Res 2004, 10:6830-6839.
49. Giles F.J., Cortes J.E., Kantarjian H.M., O'Brien S.M., Estey E., Beran M. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leuk Res 2004, 28:353-357.
50. Eom K.S., Min W.S., Kim H.J., et al. FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia. Med Oncol 2011, 28(SUPPL. 1):S462-S470.
51. Tsimberidou A.M., Estey E., Cortes J.E., et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 2003, 52:449-452.
52. Tsimberidou A.M., Estey E., Cortes J.E., et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003, 97:1481-1487.
53. Jabbour E., Garcia-Manero G., Cortes J., et al. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2012, 12:244-251.
54. Fong C.Y., Grigoriadis G., Hocking J., et al. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effectivesalvage therapy option for acute myeloid leukemia at first relapse. Leuk Lymphoma 2013, 54:336-341.
55. Robak T., Korycka A., Robak E. Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies. Recent Pat Anticancer Drug Discov 2006, 1:23-38.
56. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992, 340:952-956.
57. Santana V.M., Mirro J., Harwood F.C. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 1991, 9:416-422.
58. Santana V.M., Mirro J., Kearns C. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992, 10:364-370.
59. Krance R.A., Hurwitz C.A., Head D.R., et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic disease. J Clin Oncol 2001, 19:2804-2811.
60. Santana V.M., Hurwitz C.A., Blakley R.L., et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994, 84:1237-1242.
61. Kornblau S.M., Gandhi V., Andreeff H.M., et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine+cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 1996, 10:1563-1569.
62. Gandhi V., Estey E., Keating M.J., et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic and molecular interactions. Blood 1996, 87:256-264.
63. Gordon M.S., Young M.L., Tallman M.D., et al. Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995. Leuk Res 2000, 24:871-875.
64. Van den Neste E., Martiat P., Mineur P., et al. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. Ann Hematol 1998, 76:19-23.
65. Vahdat L., Wong E., Wile M., Rosenblum M., Foley K.M., Warell R.P. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeleoid leukemia. Blood 1994, 84:3429-3434.
66. Robak T., Wrzesień-Kuś A., Lech-Marańda E., Kowal M., Dmoszyńska A. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 2000, 39:121-129.
67. Wrzesień-Kuś A., Robak T., Lech-Marańda E., et al. Polish Adult Leukemia Group. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). Eur J Haematol 2003, 71:155-162.
68. Price S.L., Lancet J.E., George T.J., et al. Salvage chemotherapy regimens for acute myeloid leukemia: is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res 2011, 35:301-304.
69. Wrzesień-Kuś A., Robak T., Wierzbowska A., et al. A multicenter open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol 2005, 84:557-564.
70. Wierzbowska A., Robak T., Pluta A., et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol 2008, 80:115-126.
71. Martin M.G., Welch J.S., Augustin K., Hladnik L., DiPersio J.F., Abboud C.N. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma 2009, 9:298-301.
72. Juliusson G., Lofgren C., Mollgard L., et al. No additional toxicity from cladribine (CdA) as primary treatment of acute myeloid leukemia in elderly patients: results from a randomized phase II study from the Leukemia Group of Middle Sweden (LGMS). Blood 2001, 98:123a. (Abstract).
73. Hołowiecki J., Grosicki S., Robak T., et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter phase III study. Leukemia 2004, 18:989-997.
74. Holowiecki J., Grosicki S., Giebel S., et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012, 30:2441-2448.
75. Inaba H., Stewart C.F., Crews K.R. Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer 2010, 116:98-105.
76. Rubnitz J.E., Crews K.R., Pounds S., et al. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia 2009, 23:1410-1416.
77. Ghanem H., Jabbour E., Faderl S., Ghandhi V., Plunkett W., Kantarjian H. Clofarabine in leukemia. Expert Rev Hematol 2010, 3:15-22.
78. Ghanem H., Kantarjian H., Ohanian M., Jabbour E. The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma 2012, [Epub ahead of print].
79. Lech-Maranda E., Korycka A., Robak T. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity. Mini Rev Med Chem 2009, 9:805-812.
80. Bonate P.L., Arthaud L., Cantrell W.R., Stephenson K., Secrist J.A., Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006, 5:855-863.
81. King K.M., Damaraju V.L., Vickers M.F., et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol. Pharmacol 2006, 69:346-353.
82. Majda K., Lubecka K., Kaufman-Szymczyk A., Fabianowska-Majewska K. Clofarabine (2-chloro-2'-fluoro-2'-deoxyarabinosyladenine)-biochemical aspects of anticancer activity. Acta Pol Pharm 2011, 68:459-466.
83. Kantarjian H., Gandhi V., Cortes J., et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003, 102:2379-2386.
84. Kantarjian H.M., Gandhi V., Kozuch P., et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003, 21:1167-1173.
85. Burnett A.K., Russell N., Kell J.W. A Phase 2 evaluation of single agent clofarabine treatment for older patients with AML who are not considered fit forintensive chemotherapy. Blood (ASH Annual Meeting Abstracts) 2004, 104:248a. (Abstract 869).
86. Burnett A.K., Baccarani M., Johnson P. Effectiveness of clofarabine in eldery AML patients with adverse cytogenetics unfit for intensive chemotherapy. Blood (ASH Annual Meeting Abstracts) 2006, 108:562a. (Abstract 1985).
87. Jeha S., Gandhi V., Chan K.W., et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004, 103:784-789.
88. Kantarjian H.M., Jeha S., Ganhi V., Wess M., Faderl S. Clofarabine: past present and future. Leuk lymphoma 2007, 48:1922-1930.
89. Kantarjian H.M., Erba H.P., Claxton D., et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavourable prognostic factors. J Clin Oncol 2010, 28:549-555.
90. Faderl S., Gandhi V., O'Brien S., et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005, 105:940-947.
91. Faderl S., Gandhi V., Verstovsck S. Clofarabine plus cytarabine (Ara-C) combination is active in newly diagnosed patients (PTS)≤age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 2004, 104:250a. (Abstract 875).
92. Faderl S., Verstovsek S., Cortes J., Kantarjian H.M. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50years of age or older. Blood 2006, 108:45-51.
93. Faderl S., Ravandi F., Huang X., et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008, 112:1638-1645.
94. Faderl S., Wetzler M., Rizzieri D., et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol 2012, 30:2492-2499.
95. Faderl S., Ravandi F., Huang X., et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012, 118:4471-4477.
96. Burnett A.K., Russell N.H., Kell J., et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010, 28:2389-2395.
97. Becker P.S., Kantarjian H.M., Appelbaum F.R., et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 2011, 155:182-189.
98. Foster M.C., Amin C., Voorhees P.M., et al. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia. Leuk Lymphoma 2012, 53:1331-1337.
99. Amadori S., Stasi R., Martelli A.M., et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol 2012, 156:205-212.
100. Jeha S., Razzouk B., Rytting M., et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2009, 27:4392-4397.
101. Miano M., Pistorio A., Putti M.C., et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma 2012, 53:1693-1698.
102. Inaba H., Rubnitz J.E., Coustan-Smith E., et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011, 20:3293-3300.
103. Jeha S., Razzouk B., Rytting M., et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2009, 10(27):4392-4397.
104. Jeha S., Gaynon P.S., Razzouk B.I., et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006, 24:1917-1923.
105. Barba P., Sampol A., Calbacho M. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience. Am J Hematol 2012, 87:631-634.
106. Advani A.S., Gundacker H.M., Sala-Torra O., et al. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol 2010, 151:430-434.
107. Locatelli F., Testi A.M., Bernardo M.E., et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children withrefractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 2009, 147:371-378.
108. Hijiya N., Thomson B., Isakoff M.S., et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011, 118:6043-6049.
109. Steinherz P.G., Shukla N., Kobos R., Steinherz L. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer 2010, 54:687-693.
110. O'Connor D., Sibson K., Caswell M., et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory pediatric acute lymphoblastic leukaemia. Br J Haematol 2011, 154:482-485.
111. Roecker A.M., Allison J.C., Kisor D.F. Nelarabine: efficacy in the treatment of clinical malignancies. Future Oncol 2006, 2:441-448.
112. Lambe C.U., Averett D.R., Paff M.T., et al. 2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res 1995, 55:3352-3356.
113. Rodriguez C.O., Mitchell B.S., Ayres M., Eriksson S., Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 2002, 62:3100-3105.
114. Kisor D.F. Nelarabine use in leukemias. Drugs Today 2006, 42:455-465.
115. Ghandi V., Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol 2006, 18:584-590.
116. Kurtzberg J., Ernst T.J., Keating M.J., et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005, 23:3396-3403.
117. Berg S.L., Blaney S.M., Devidas M., et al. Phase II study of nelarabine (compound 506U78) in children andyoung adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005, 23:3376-3382.
118. DeAngelo D.J., Yu D., Johnson J.L., et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007, 109:5136-5142.
119. Dunsmore K.P., Devidas M., Linda S.B., et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 2012, 30:2753-2759.
120. Commander L.A., Seif A.E., Insogna I.G., Rheingold S.R. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol 2010, 150:345-351.
121. Gökbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 2011;118:3504-11.
122. Buie L.W., Epstein S.S., Lindley C.M. Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther 2007, 29:1887-1899.
123. Cohen M.H., Johnson J.R., Justice R., Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist 2008, 13:709-714.
124. Al-Kali A., Gandhi V., Ayoubi M., Keating M., Ravandi F. Forodesine: review of preclinical and clinical data. Future Oncol 2010, 6:1211-1217.
125. Korycka A., Błoński J.Z., Robak T. Forodesine (BCX-1777, immucillin H)-a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev Med Chem 2007, 7:976-983.
126. Evans G.B., Furneaux R.H., Lewandowicz A., Schramm V.L., Tyler P.C. Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. J Med Chem 2003, 46:5271-5276.
127. Miles R.W., Tyler P.C., Furneaux R.H., Bagdassarian C.K., Schramm V.L. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry 1998, 37:8615-8621.
128. Bantia S., Miller P.J., Parker C.D., Ananth S.L., Horn L.H., Kilpatrick J.M., et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)-a novel potent and orally active immunosuppressive agent. Intern Immunopharmacol 2001, 1:1199-1210.
129. Balakrishnan K., Nimmanapalli R., Ravandi F., Keating M.J., Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2006, 108:2392-2398.
130. Gandhi V., Kilpatrick J.M., Plunkett W., et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 2005, 106:4253-4260.
131. Homminga I., Zwaan C.M., Manz C.Y., et al. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. Blood 2011, 118:184-190.
132. Furman R.R., Iosava G., Isola L., et al. Forodesine (FodosineTM), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients (Phase II study). Blood (ASH Annual Meeting Abstracts) 2005, 106:259a. (Abstract 881).
133. Stelljes M., Kienast J., Berning B., et al. Forodesine in patients with refractory/relapsed T-ALL can induce prolonged stable remission with minimal toxicity before and after allogeneic hematopoietic stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2006, 106:427a. (Abstract 5340).
134. Gore L., Stelljes M., Quinones R. Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?. Semin Oncol 2007, 34(6 SUPPL. 5):S35-S39.
135. Furman R.R., Gandhi V.V., Bennett J.C., Bantia S., Kilpatrick J.M. Intravenous Forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-Cell acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2004, 104:750a. (Abstract 2743).
136. Ritchie E., Gore L., Roboz G.J. Phase II study of forodesine, a PNP. Blood (ASH Annual Meeting Abstracts) 2006, 108:533a. (Abstract 1881).